12
Participants
Start Date
March 10, 2022
Primary Completion Date
September 3, 2024
Study Completion Date
October 30, 2024
TARA-002
Phase 1a, Dose Escalation: First, up to 3 dose levels of TARA-002 (10 KE → 20 KE → 40 KE) will be tested sequentially with 6 weekly intravesical doses starting with the lowest dose using a 3+3 design in a dose escalation manner until the RP2D has been established. If the MTD is not reached, additional cohorts of dose levels higher than 40 KE may be explored.
Spitalul Clinic de Nefrologie Carol Davila, Bucharest
Premier Medical Group of the Hudson Valley, Poughkeepsie
University of Rochester, Department of Urology, Rochester
Chesapeake Urology Research Associates, Baltimore
Carolina Urologic Research Center, Myrtle Beach
Mayo Clinic, Jacksonville
Urology Associates PC, Nashville
Mayo Clinic, Rochester
Tulane Medical Center, New Orleans
UT Health San Antonio, San Antonio
USC Norris Cancer Center, Los Angeles
New Jersey Urology, Mount Laurel
"PMSI Republican Clinical Hospital T. Mosneaga, ARENSIA Exploratory Medicine Phase I Unit", Chisinau
Arensia Kapitanivka, Kapitanivka
Lead Sponsor
Protara Therapeutics
INDUSTRY